Richter Gedeon Vegyeszeti Gyar Nyrt represents strong values and a robust corporate philosophy. With a focus on pharmaceuticals and healthcare, Richter Gedeon aims to provide innovative solutions and improve the well-being of society. The company upholds integrity, ethics, and excellence in all its endeavors, ensuring high product quality and patient safety. Through continuous research and development, Richter Gedeon strives for scientific advancements and breakthrough therapies. Commitment to environmental sustainability and social responsibility is also an integral part of their corporate philosophy, contributing to a healthier and more sustainable future.

Richter Gedeon Vegyeszeti Gyar Nyrt, commonly known as Richter, is primarily present in several countries and regions. These include Hungary, its home country where it is headquartered in Budapest. Richter also has a significant presence in other European countries such as Romania, Poland, Czech Republic, Slovakia, and Russia. It has further expanded its operations to countries in Asia, including China and Vietnam. Additionally, Richter has a presence in the United States, where it has a subsidiary called Richter-Helm BioLogics.

Richter Gedeon Vegyeszeti Gyar Nyrt, a prominent pharmaceutical company, has achieved several significant milestones throughout its history. The company has established itself as a leader in the development and production of innovative medicines and healthcare products. Richter Gedeon Nyrt has successfully introduced numerous breakthrough drugs, addressing various therapeutic areas such as women's health, central nervous system disorders, and cardiovascular diseases. With a strong commitment to research and development, Richter Gedeon Nyrt has consistently focused on expanding its product portfolio and enhancing patient outcomes. This dedication to excellence has propelled the company to become a trusted name in the pharmaceutical industry.

Richter Gedeon Vegyészeti Gyár Nyrt., commonly known as Richter, is a Hungarian pharmaceutical company. Established in 1901, Richter has a rich history and extensive background in the pharmaceutical industry. With over a century of experience, the company has grown to become a leading player in Central and Eastern Europe, focusing on developing, manufacturing, and marketing innovative pharmaceutical products. Richter specializes in a wide range of therapeutic areas, including women's healthcare, central nervous system disorders, cardiovascular diseases, and gastroenterology. Through continuous research and development efforts, Richter strives to provide high-quality and affordable medications to improve the well-being of patients worldwide.

The main competitors of Richter Gedeon Vegyeszeti Gyar Nyrt in the market include pharmaceutical companies such as Novartis, Sanofi, and Roche. With its strong presence in the pharmaceutical industry, Richter Gedeon Vegyeszeti Gyar Nyrt competes against these global players in various therapeutic areas. The company's innovative products, extensive research and development efforts, and strategic partnerships enable it to withstand competition and maintain its market position. Richter Gedeon Vegyeszeti Gyar Nyrt continues to focus on delivering high-quality pharmaceutical solutions to meet the evolving needs of patients worldwide.

Richter Gedeon Vegyeszeti Gyar Nyrt is primarily active in the pharmaceutical industry.

The business model of Richter Gedeon Vegyeszeti Gyar Nyrt, also known as Richter, is focused on pharmaceutical and biotechnology research, development, and manufacturing. As a leading Hungarian company, Richter engages in the production of prescription drugs, over-the-counter medications, and active pharmaceutical ingredients (APIs). The company specializes in the fields of gynecology, central nervous system disorders, cardiovascular ailments, and osteoporosis. With a wide portfolio of innovative pharmaceutical products, Richter aims to improve the quality of life and well-being of patients worldwide. Combining their scientific expertise with cutting-edge technology, Richter strives to provide effective and safe healthcare solutions, contributing to the advancement of medicine globally.

สัดส่วนราคาต่อกำไรของ Richter Gedeon Vegyeszeti Gyar Nyrt คือ 7.22

KUV ของ Richter Gedeon Vegyeszeti Gyar Nyrt คือ 2.08

AlleAktien คุณภาพสกอร์สำหรับ Richter Gedeon Vegyeszeti Gyar Nyrt คือ 9/10.

คาดหวัง Richter Gedeon Vegyeszeti Gyar Nyrt มียอดขายอยู่ที่ 871.89 ล้านล้าน HUF

กำไร คาดหวัง Richter Gedeon Vegyeszeti Gyar Nyrt คือ 251.45 ล้านล้าน HUF

Richter Gedeon Vegyeszeti Gyar Nyrt is a multinational pharmaceutical company based in Budapest, Hungary. The company specializes in the production of prescription and OTC medications, chemicals and active ingredients, as well as the development of generic products. The main business areas of Richter Gedeon are human pharmaceuticals, pharmaceutical chemistry, and biotechnology. The company operates research and development (R&D) in all areas and has state-of-the-art facilities in research, development, and production. The human pharmaceutical division includes the manufacture of drugs for the treatment of various diseases, such as schizophrenia, epilepsy, Parkinson's disease, migraines, gynecology, and gastroenterology. The products are sold worldwide and are available in various forms such as tablets, capsules, injections, and patches. The pharmaceutical chemistry division produces high-performance chemicals and active ingredients for the pharmaceutical industry. The company has been a leading player in this field for many years and collaborates closely with other pharmaceutical companies to develop cost-effective active agents. The range of products includes antibiotics, antidepressants, antithrombotics, antihypertensives, and hormones. The biotechnology division of Richter Gedeon focuses on the identification and development of proteins, peptides, and antibodies. The company invests heavily in R&D and has successfully developed a range of innovative biological products. The new products include MABp1, a biological medicine for the treatment of pain and inflammation, currently being tested in Phase III clinical trials, as well as a range of biosimilars, including the biosimilar version of Herceptin, a breast cancer medication. Richter Gedeon also has a strong presence in emerging markets. The company has subsidiaries in over 40 countries and has joint ventures with companies in China, Russia, and India. The company has also built a strong marketing and distribution network to sell its products worldwide. In Europe, Richter Gedeon is a market leader in several countries and focuses on expanding its presence in North America and Asia. In summary, Richter Gedeon Vegyeszeti Gyar Nyrt offers a wide range of pharmaceutical products, from drugs for the treatment of specific diseases to chemical agents, biotechnology products, and biosimilars. The company has a strong R&D base and invests in innovative products, joint ventures, and international expansion to strengthen its position in emerging markets.

Richter Gedeon Vegyeszeti Gyar Nyrt จ่ายเงินปันผล 225.17 HUF ผ่าน ครั้งในหนภายในหนึ่งปี.

ปัจจุบันไม่สามารถคำนวณเงินปันผลสำหรับ Richter Gedeon Vegyeszeti Gyar Nyrt หรือบริษัทไม่จ่ายเงินปันผล.

ISIN ของ Richter Gedeon Vegyeszeti Gyar Nyrt คือ HU0000123096

WKN ของ Richter Gedeon Vegyeszeti Gyar Nyrt คือ A1W16N.

ตัวย่อของ Richter Gedeon Vegyeszeti Gyar Nyrt คือ RICHTER.BD

ภายในช่วง 12 เดือนที่ผ่านมา Richter Gedeon Vegyeszeti Gyar Nyrt จ่ายเงินปันผลทั้งหมด 391.32 HUF นี้เทียบเท่ากับอัตราผลตอบแทนจากเงินปันผลประมาณ 3.98 % สำหรับ 12 เดือนข้างหน้า Richter Gedeon Vegyeszeti Gyar Nyrt คาดว่าจะจ่ายเงินปันผลทั้งหมด 438.52 HUF

อัตราผลตอบแทนเงินปันผลของ Richter Gedeon Vegyeszeti Gyar Nyrt ในปัจจุบันคือ 3.98 %

Richter Gedeon Vegyeszeti Gyar Nyrt จ่ายเงินปันผลทุกไตรมาส การจ่ายเงินปันผลจะเกิดขึ้นในเดือน กรกฎาคม, กรกฎาคม, กรกฎาคม, กรกฎาคม

Richter Gedeon Vegyeszeti Gyar Nyrt จ่ายเงินปันผลทุกปีในช่วง 23 ปีที่ผ่านมา.

คาดว่าในช่วง 12 เดือนข้างหน้าจะมีการจ่ายเงินปันผลทั้งหมด 438.52 HUF ซึ่งเทียบเท่ากับผลตอบแทนจากเงินปันผลร้อยละ 4.06 %

Richter Gedeon Vegyeszeti Gyar Nyrt ถูกจัดให้อยู่ในภาคส่วน 'สุขภาพ'

เพื่อรับเงินปันผลล่าสุดของ Richter Gedeon Vegyeszeti Gyar Nyrt ในวันที่ 13/6/2567 ที่มูลค่า 431.983 HUF คุณจะต้องถือหุ้นไว้ในพอร์ตก่อนวันที่เป็น Ex-Tag ในวันที่ 5/6/2567

การจ่ายเงินปันผลครั้งล่าสุดเกิดขึ้นเมื่อวันที่ 13/6/2567

ในปี 2023 บริษัท Richter Gedeon Vegyeszeti Gyar Nyrt ได้จ่ายเงินปันผลเป็นจำนวน 225.172 HUF

เงินปันผลของ Richter Gedeon Vegyeszeti Gyar Nyrt จะถูกจ่ายใน HUF